Advertisement

International Journal of Clinical Pharmacy

, Volume 39, Issue 4, pp 704–711 | Cite as

Drug utilization evaluation of albumin in a teaching hospital of Mashhad, Iran: an interventional pre–post design study

  • Farzaneh Zolfagharian
  • Saba Ghazanfari
  • Sepideh Elyasi
  • Paria Iraji
  • Mohammad Reza Saberi
  • Nasser Vahdati-Mashhadian
  • Amir Hooshang Mohammadpour
Research Article
  • 261 Downloads

Abstract

Background Albumin is a protein colloidal solution with limited availability and high cost. It should be used in such approved indications as paracentesis, extensive burn, spontaneous bacterial peritonitis, and nephrotic syndrome. Objectives The aim of this study was to evaluate and compare the appropriateness of albumin usage before and after an evidence-based guideline. Setting Four wards of Imam Reza Hospital, Mashhad, Iran. Method An interventional pre–post design study was performed on 2 groups of patients; in gGroup 1 as a preparation phase group in 6 months from February 2015 to July 2015 and Group 2 as an interventional group from September 2015 to February 2016. A guideline for proper indications of albumin, designed and finalized based on the physicians’ comments, was implemented in Group 2. Main outcome measure The pattern of albumin consumption. Results Fifty patients were evaluated in each group. The implementation of the guideline resulted in reduction of improper albumin use from 62 to 57.5%, which was not statistically significant; however., it reduced inappropriate dose and duration of albumin therapy (55.5–16.7%), the number of consumed albumin vial, and the average cost for each patient (317.78 ± 3.15–149.81 ± 1.91 USD) significantly, as well. Conclusion This study illustrated that in this hospital in most cases, albumin was used inappropriately and at an alarming rate. This improved after the introduction of an evidence-based guideline. Moreover, guideline implementation resulted in significant cost reduction.

Keywords

Albumin Cost reduction Drug use evaluation (DUE) Inappropriate use Intervention Iran Teaching hospital 

Notes

Acknowledgements

This study is part of a research thesis for a Pharm.D. degree at Mashhad University of Medical Sciences. The authors are thankful for the funding of this study by the Research Council of Mashhad University of Medical Sciences.

Funding

Mashhad University of Medical Sciences.

Conflicts of interest

None.

Supplementary material

11096_2017_458_MOESM1_ESM.pdf (369 kb)
Supplementary material 1 (PDF 368 kb)
11096_2017_458_MOESM2_ESM.pdf (173 kb)
Supplementary material 2 (PDF 172 kb)

References

  1. 1.
    Kazemi Y, Hadavand N, Hayatshahi A, Torkamandi H, Gholami K, Hadjibabaie M, et al. Albumin utilization in a teaching hospital in Tehran: time to revise the prescribing strategies. J Pharm Care. 2013;1(4):127–32.Google Scholar
  2. 2.
    Bowman I. Drug use evaluation is DUE: healthcare utilization evaluation is over-DUE. Hosp Pharm. 1996;3:5–8.Google Scholar
  3. 3.
    Talasaz AH, Jahangard-Rafsanjani Z, Ziaie S, Fahimi F. Evaluation of the pattern of human albumin utilization at a university affiliated hospital. Arch Iran Med. 2012;15(2):85–7.PubMedGoogle Scholar
  4. 4.
    Namazi S, Karimzadeh I. Drug utilization evaluation of unfractionated heparin in a cardiac care unit in Iran. J Pharm Res. 2011;4(5):1470–2.Google Scholar
  5. 5.
    Mahmoudi L, Karamikhah R, Mahdavinia A, Samiei H, Petramfar P, Niknam R. Implementation of pharmaceutical practice guidelines by a project model based clinical and economic impact. Medicine. 2015;94(42):e1744.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jahangard-Rafsanjani Z, Javadi MR, Torkamandi H, Alahyari S, Hajhossein Talasaz A, Gholami KH. The Evaluation of albumin utilization in a teaching university hospital in Iran. IJPR. 2011;10(2):385–90.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Caraceni P, Domenicali M, Tovoli A, Napoli L, Serena Ricci C, Tufoni M, Bernard M. Clinical indications for the albumin use: still a controversial issue. Eur J Intern Med. 2013;24:721–8.CrossRefPubMedGoogle Scholar
  8. 8.
    WHO medicines strategy: framework for actions in essential drugs and medicines policy; 2000–2003. Geneva: World Health Organization. From World Health Organization on the World Wide Web: http://apps.who.int/medicinedocs/pdf/whozip16e/whozip16e.pdf.
  9. 9.
    American Hospital Formulary Service® (AHFS™) Drug Information 2009. Bethesda: American Society of Health System Pharmacists. From AHFS on the World Wide Web: http://www.ahfsdruginformation.com/.
  10. 10.
    Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossettias G. Recommendations for the use of albumin and immunoglobulins. Blood Transfus. 2009;7(3):216–34.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Aramwit P, Kasettratat N. Evaluation of serum albumin utilization in inpatient at a private hospital in Bangkok. Yakugaku Zasshi. 2004;124(9):631–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Vargas E, de Miguel V, Portole A, Avendano C, Ambit M, Torralba A, Moreno A. Use of albumin in two Spanish university hospitals. Eur J Clin Pharmacol. 1997;52:465–70.CrossRefPubMedGoogle Scholar
  13. 13.
    Somers A, Bauters T, Robays H, Bogaert M, Colardyn F. Evaluation of human albumin use in a university hospital in Belgium. Pharm World Sci. 2002;24(3):111–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Tanzi M, Gardner M, Megellas M, Lucio S, Restino M. Evaluation of the appropriate use of albumin in adult and pediatric patients. Am J Health Sys Pharm. 2003;60:1330–5.Google Scholar
  15. 15.
    Marwick C. Pharmacoeconomics: is a drug worth its cost? JAMA. 1994;272:1395.CrossRefPubMedGoogle Scholar
  16. 16.
    Marshall J, Finn CA, Theodore AC. Impact of a clinical pharmacist enforced intensive care unit sedation protocol on duration of mechanical ventilation and hospital stay. Crit Care Med. 2008;36:427–33.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing 2017

Authors and Affiliations

  • Farzaneh Zolfagharian
    • 1
  • Saba Ghazanfari
    • 2
  • Sepideh Elyasi
    • 3
  • Paria Iraji
    • 3
  • Mohammad Reza Saberi
    • 4
  • Nasser Vahdati-Mashhadian
    • 5
    • 6
  • Amir Hooshang Mohammadpour
    • 3
    • 7
  1. 1.Department of Pharmacology, School of MedicineMashhad University of Medical SciencesMashhadIran
  2. 2.DUE Center, Imam Reza HospitalMashhad University of Medical SciencesMashhadIran
  3. 3.Department of Clinical Pharmacy, School of PharmacyMashhad University of Medical SciencesMashhadIran
  4. 4.Medical Chemistry Department, School of PharmacyMashhad University of Medical SciencesMashhadIran
  5. 5.Medical Toxicology Research CenterMashhad University of Medical SciencesMashhadIran
  6. 6.Department of Pharmacodynamics and Toxicology, School of PharmacyMashhad University of Medical SciencesMashhadIran
  7. 7.Pharmaceutical Research CenterMashhad University of Medical SciencesMashhadIran

Personalised recommendations